Search

Your search keyword '"Yuxia Bo"' showing total 3 results
Start Over Author "Yuxia Bo" Journal cell reports
3 results on '"Yuxia Bo"'

1. Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine

Author

Alexandra Tauzin, Alexandre Nicolas, Shilei Ding, Mehdi Benlarbi, Halima Medjahed, Debashree Chatterjee, Katrina Dionne, Shang Yu Gong, Gabrielle Gendron-Lepage, Yuxia Bo, Josée Perreault, Guillaume Goyette, Laurie Gokool, Pascale Arlotto, Chantal Morrisseau, Cécile Tremblay, Valérie Martel-Laferrière, Gaston De Serres, Inès Levade, Daniel E. Kaufmann, Marceline Côté, Renée Bazin, and Andrés Finzi

Subjects
CP: Immunology, Biology (General), QH301-705.5
Abstract

Summary: Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants have recently emerged, becoming the dominant circulating strains in many countries. These variants contain a large number of mutations in their spike glycoprotein, raising concerns about vaccine efficacy. In this study, we evaluate the ability of plasma from a cohort of individuals that received three doses of mRNA vaccine to recognize and neutralize these Omicron subvariant spikes. We observed that BA.4/5 and BQ.1.1 spikes are markedly less recognized and neutralized compared with the D614G and other Omicron subvariant spikes tested. Also, individuals who have been infected before or after vaccination present better humoral responses than SARS-CoV-2-naive vaccinated individuals, thus indicating that hybrid immunity generates better humoral responses against these subvariants.

Published
2023
Full Text
View/download PDF

2. SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses

Author

Debashree Chatterjee, Alexandra Tauzin, Lorie Marchitto, Shang Yu Gong, Marianne Boutin, Catherine Bourassa, Guillaume Beaudoin-Bussières, Yuxia Bo, Shilei Ding, Annemarie Laumaea, Dani Vézina, Josée Perreault, Laurie Gokool, Chantal Morrisseau, Pascale Arlotto, Éric Fournier, Aurélie Guilbault, Benjamin Delisle, Inès Levade, Guillaume Goyette, Gabrielle Gendron-Lepage, Halima Medjahed, Gaston De Serres, Cécile Tremblay, Valérie Martel-Laferrière, Daniel E. Kaufmann, Renée Bazin, Jérémie Prévost, Sandrine Moreira, Jonathan Richard, Marceline Côté, and Andrés Finzi

Subjects
Adult, Male, Vaccines, Synthetic, Time Factors, SARS-CoV-2, Vaccination, Immunization, Secondary, Quebec, Middle Aged, Antibodies, Viral, Antibodies, Neutralizing, General Biochemistry, Genetics and Molecular Biology, Cohort Studies, Young Adult, HEK293 Cells, Spike Glycoprotein, Coronavirus, Humans, Female, mRNA Vaccines, Vaccine Potency, BNT162 Vaccine, Immunization Schedule, Aged
Abstract

SUMMARYContinuous emergence of SARS-CoV-2 variants of concern (VOC) is fueling the COVID-19 pandemic. Omicron (B.1.1.529), is rapidly spreading worldwide. The large number of mutations in its Spike raised concerns about a major antigenic drift that could significantly decrease vaccine efficacy and infection-induced immunity. A long interval between BNT162b2 mRNA doses was shown to elicit antibodies that efficiently recognize Spikes from different VOCs. Here we evaluated the recognition of Omicron Spike by plasma from a cohort of SARS-CoV-2 naïve and previously-infected individuals that received their BNT162b2 mRNA vaccine 16-weeks apart. Omicron Spike was recognized less efficiently than D614G, Alpha, Beta, Gamma and Delta Spikes. We compared to plasma activity from participants receiving a short (4-weeks) interval regimen. Plasma from individuals of the long interval cohort recognized and neutralized better the Omicron Spike compared to those that received a short interval. Whether this difference confers any clinical benefit against Omicron remains unknown.

Published
2021

3. A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses

Author

Alexandra Tauzin, Shang Yu Gong, Debashree Chatterjee, Shilei Ding, Mark M. Painter, Rishi R. Goel, Guillaume Beaudoin-Bussières, Lorie Marchitto, Marianne Boutin, Annemarie Laumaea, James Okeny, Gabrielle Gendron-Lepage, Catherine Bourassa, Halima Medjahed, Guillaume Goyette, Justine C. Williams, Yuxia Bo, Laurie Gokool, Chantal Morrisseau, Pascale Arlotto, Renée Bazin, Judith Fafard, Cécile Tremblay, Daniel E. Kaufmann, Gaston De Serres, Jonathan Richard, Marceline Côté, Ralf Duerr, Valérie Martel-Laferrière, Allison R. Greenplate, E. John Wherry, and Andrés Finzi

Subjects
COVID-19 Vaccines, SARS-CoV-2, Vaccination, Humans, COVID-19, Viral Vaccines, Antibodies, Viral, BNT162 Vaccine, General Biochemistry, Genetics and Molecular Biology
Abstract

Due to the recrudescence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections worldwide, mainly caused by the Omicron variant of concern (VOC) and its sub-lineages, several jurisdictions are administering an mRNA vaccine boost. Here, we analyze humoral responses induced after the second and third doses of an mRNA vaccine in naive and previously infected donors who received their second dose with an extended 16-week interval. We observe that the extended interval elicits robust humoral responses against VOCs, but this response is significantly diminished 4 months after the second dose. Administering a boost to these individuals brings back the humoral responses to the same levels obtained after the extended second dose. Interestingly, we observe that administering a boost to individuals that initially received a short 3- to 4-week regimen elicits humoral responses similar to those observed in the long interval regimen. Nevertheless, humoral responses elicited by the boost in naive individuals do not reach those present in previously infected vaccinated individuals.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results